Program for Clinical Seminar

12:20 ~ 13:20, Monday, December 10

**C1 Clinical Seminar 1** Room B: 401+402+403

Chairperson: Kiyoshi Takeda (Laboratory of Immune Regulation, Department of Microbiology and Immunology, Graduate School of Medicine, WPI Immunology Frontier Research Center, Osaka University)

**The role of IL-12/23 in the pathogenesis of inflammatory bowel disease**

Scott E Plevy IBD Disease Area Stronghold Lead R&D, The Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, PA, USA

Janssen Pharmaceutical K.K.

12:20 ~ 13:20, Monday, December 10

**C2 Clinical Seminar 2** Room C: 404+405+406

Chairperson: Yoshiya Tanaka (The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan)

**Cytokine control of Arthritis**

Georg Schett University of Nürnberg-Erlangen, Germany

Pfizer Japan Inc.

12:20 ~ 13:20, Monday, December 10

**C3 Clinical Seminar 3** Room D: 409+410

*This seminar will be presented in Japanese.*

Chairperson: Atsushi Kawakami (Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences)

**JAK inhibitors as a novel therapy in rheumatoid arthritis**

Akio Morinobu Rheumatology, Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan

Eli Lilly Japan K.K.

12:20 ~ 13:20, Monday, December 10

**C4 Clinical Seminar 4** Room H: 503

*This seminar will be presented in Japanese.*

Chairperson: Takayuki Sumida (Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan)

**Positioning of tacrolimus in the treatment of lupus nephritis**

Naoto Tamura Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyo, Japan

AYUMI Pharmaceutical Corporation
**C5 Clinical Seminar 5**  Room B: 401+402+403

Chairperson: Takao Fujii (Department of Rheumatology and Clinical Immunology, Wakayama Medical University)

*This seminar will be presented in Japanese.*

**Basic research in immunology and its clinical applications, including our approach on immunometabolism, ANCA-associated vasculitis, and CAR-T therapy**

Atsushi Kumanogoh  Osaka University Graduate School of Medicine, Osaka, Japan

Bristol-Myers Squibb K.K. / ONO PHARMACEUTICAL CO., LTD.

---

**C6 Clinical Seminar 6**  Room D: 409+410

Chairperson: Hiroaki Niino (Department of Medical Education, Faculty of Medical Sciences, Kyushu University)

*This seminar will be presented in Japanese.*

**The possibility of induced pluripotent stem cells for investigation of autoimmune diseases**

Hirofumi Shoda  Department of Allergy and Rheumatology, Graduation School of Medicine, the University of Tokyo, Tokyo, Japan

GlaxoSmithKline K. K.

---

**C7 Clinical Seminar 7**  Room H: 503

Chairperson: Keishi Fuji (The University of Tokyo)

*This seminar will be presented in Japanese.*

**Synovial phenotype and behavior of synoviocytes under TNFa and other inflammatory cytokines/growth factors**

Shinsuke Yasuda  Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

Janssen Pharmaceutical K.K. / Mitsubishi Tanabe Pharma Corporation

---

**C8 Clinical Seminar 8**  Room D: 409+410

Chairperson: Tatsuya Atsumi (Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University)

*This seminar will be presented in Japanese.*

**Contribution of Type I interferon signal to autoimmune and autoinflammatory disease**

Keishi Fujio  Department of Allergy and Rheumatology, University of Tokyo, Tokyo, Japan

Sanofi K.K.

---

**C9 Clinical Seminar 9**  Room E: 411+412

Chairperson: Kazuhiko Yamamoto (RIKEN)

**Defining the architecture of rheumatoid arthritis at the single cell level**

Soumya Raychaudhuri  Brigham and Women’s Hospital, Boston, MA

AbbVie GK, Eisai Co., Ltd.
**Clinical Seminar 10**  Room G: 502

Chairperson: Kunihiro Yamaoka (Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine)

**Osteoimmunology and RANKL inhibition**
Hiroshi Takayanagi  Department of Immunology, Graduate School of Medicine and Faculty of Medicine The University of Tokyo, Tokyo, Japan

DAIICHI SANKYO COMPANY, LIMITED

---

**Clinical Seminar 11**  Room H: 503

Chairperson: Tsutomu Takeuchi (Keio University School of Medicine)

**Bedside to bench: what have immune therapies taught us about autoimmunity-The importance of Interleukin-6 signaling inhibition in autoimmune diseases**

Iain McInnes  Professor of Experimental Medicine, Director of Research Institute (Immunology), University of Glasgow, Glasgow, UK

CHUGAI PHARMACEUTICAL CO., LTD.